Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
----------
AIM - WINNERS
----------
Futura Medical, more than doubles to 38.8 pence, 12-month range 7.5p-47.4p. The pharmaceutical company says the European Union is to certificate its MED3000 as a Class 2B approved medical device. Once the certificate is received, Futura's topical gel formulation MED3000 will become the first pan-European topical treatment for erectile dysfunction available without the need for a doctor's prescription.
----------
ReNeuron Group, up 11% at 120.30p, 12-month range 70p-179p. The cell-based therapeutics developer unveils new collaborations and data findings on its exosome technology platform. Its exosome technology is being explored by pharmaceutical, biotechnology and academic partners as a new delivery vehicle for third-party therapeutic agents targeting the brain and other parts of the body. The company is developing its lead exosome candidate from its proprietary CTX neural stem cell line. If the data collected from the new collaborations is positive, ReNeuron believes it could seek out-licensing deals in next six months.
----------
Primorus Investments, up 13% at 5.19p, 12-month range 1.53p-5.19p. Chair Rupert Labrum buys 1.0 million shares at 4.49p each, GBP44,900, on Thursday and now holds a 21% stake.
----------
AIM - LOSERS
----------
B90 Holdings, down 38% at 20.5p, 12-month range 4.5p-38.81p. The online marketing company comments on recent share price volatility after being restored to trading on Wednesday. B90 confirms it is not in possession of any unpublished price sensitive information, and there are no further updates to Wednesday's announcement or in the context of its business generally.
----------
IDOX, down 17% at 59.24p, 12-month range 27.1p-79p. The management software provider confirms Dye & Durham does not intend to make an offer to buy the company, and it agrees to sell its Grants Consultancy business to SilverTree Equity for EUR8.1 million
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
